The pandemic then intervened, but EFEC is now back working with the LCN to develop the network and the basis for enhanced Shanghai / Cambridge business interaction and partnerships.
EFEC CEO Lily Lin is in the EFEC Lingang office, and with LCN colleagues she is engaged in a programme of visits to support these aims.
Here we highlight her recent tour of the Gluetacs Therapeutics is a biotechnology company
The Shanghai Lingang Cambridge Network (LCN) team and its UK strategic cooperation representative Ms. Lily, CEO of EFEC visited LCN member enterprise Gluetacs Therapeutics this week , to better serve member enterprises and help them to obtain more international resources and opportunities. Gluetacs gave them a warm welcome.
Gluetacs Therapeutics is a biotechnology company specialising in the development of oral protein-degrading small-molecule drugs. It was established in February 2020, and founded by several scientists who have been deeply involved in the field of protein degradation for many years.
The company has the development platform of molecular glue degrading agent (GLUE) and dual mechanism degrading agent (GLUETAC) with independent IP rights, unique differentiated technical routes, and development strategies. It also has independently established an AI screening platform, an in-vitro drug efficacy screening platform, a pharmacokinetics platform, a proteomics platform, and a tumour animal drug efficacy model platform.
Together, these realised the construction of a full-process drug research and development system.
During the visit, the company detailed its development and led the LCN team on a
tour of their research and development laboratory, on the way discussing Gluetacs’ future plans and prospects for international market expansion.
LCN and EFEC will build an international platform to assist outstanding Chinese enterprises in going global, broadening their international horizons, seeking international resources, and anticipating win-win cooperation.
